Last reviewed · How we verify
Metfomin plus Simvastatin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Metfomin plus Simvastatin (Metfomin plus Simvastatin) — Fasa University of Medical Sciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Metfomin plus Simvastatin TARGET | Metfomin plus Simvastatin | Fasa University of Medical Sciences | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Metfomin plus Simvastatin CI watch — RSS
- Metfomin plus Simvastatin CI watch — Atom
- Metfomin plus Simvastatin CI watch — JSON
- Metfomin plus Simvastatin alone — RSS
Cite this brief
Drug Landscape (2026). Metfomin plus Simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/metfomin-plus-simvastatin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing